NEW
YORK, July 26, 2023 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a
commercial-stage cancer prevention diagnostics company and a
majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ),
today announced that Shaun O'Neil, Executive Vice President
& Chief Operating Officer, will participate in a fireside chat
at the Canaccord Genuity 43rd Annual Growth
Conference on Wednesday, August 9, 2023 at 11:30 am
Eastern Time at the InterContinental Boston Hotel
in Boston, MA.
Management will also be available for one-on-one meetings with
investors at the conference. Investors who are interested in
meeting are encouraged to reach out to their representative at
Canaccord Genuity.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention
medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:
PAVM). Lucid is focused on the millions of patients with
gastroesophageal reflux disease (GERD), also known as chronic
heartburn, who are at risk of developing esophageal precancer and
cancer. Lucid's EsoGuard® Esophageal DNA Test, performed
on samples collected in a brief, noninvasive office procedure with
its EsoCheck Esophageal Cell Collection Device, is the first and
only commercially available diagnostic test capable of serving as a
widespread testing tool to prevent cancer and cancer deaths through
early detection of esophageal precancer in at-risk GERD
patients.
For more information, please visit www.luciddx.com and for more
information about its parent company PAVmed, please visit
www.pavmed.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference-301885942.html
SOURCE Lucid Diagnostics